Individual Patient Supply (UK MHRA) in United Arab Emirates

How the individual patient supply (uk mhra) pathway operates in United Arab Emirates.

About Individual Patient Supply (UK MHRA)

UK's MHRA individual-patient unlicensed-medicine supply.

How Individual Patient Supply (UK MHRA) works in United Arab Emirates

The UAE recognises a formal Named Patient / compassionate-use pathway via MOHAP and the Department of Health Abu Dhabi (DoH). Physicians apply on behalf of individual patients for drugs not registered in-country.

Patients in United Arab Emirates seeking access under Individual Patient Supply (UK MHRA) typically follow this flow: a licensed physician in United Arab Emirates issues the prescription and clinical justification, the regulator reviews and authorises, and an authorised operator coordinates import.

Documents required in United Arab Emirates

  • Physician prescription and clinical-justification letter.
  • Patient identification and consent.
  • Country-specific NPP/personal-import form.
  • Hospital or clinic attestation where required.

Typical timeline

End-to-end 2-6 weeks in most tier 1 jurisdictions. Cellular and gene therapies may require additional ethics-committee review.

Start a request

Start a request under Individual Patient Supply (UK MHRA) in United Arab Emirates

AI disclosure & medical review. Content on this page is reviewed by Reserve Meds's AI clinical and regulatory review agents. A US-licensed human pharmacist (sourced through Altima Care, a US-licensed specialty wholesaler) reviews every prescription before dispensing. Regulatory posture is AI-summarized and not legal advice; case-specific questions route to retained outside counsel. Last medically reviewed: .
WhatsApp